Veracyte Announces Novel Afirma-Based Findings That Advance Molecular Understanding Of Thyroid Cancer To Be Presented At The 2023 ATA Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Veracyte, Inc. (NASDAQ:VCYT) announced that three posters showcasing new data from the company's Afirma Genomic Sequencing Classifier (GSC) will be presented at the 2023 American Thyroid Association (ATA) Annual Meeting. The abstracts offer insights into the molecular underpinnings of thyroid nodules and tumors based on whole-transcriptome RNA sequencing data. The company believes that Afirma-based whole-transcriptome analysis will advance cancer research and may be used in clinical care.
September 21, 2023 | 8:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Veracyte's announcement of presenting new data from its Afirma GSC at the 2023 ATA Annual Meeting could potentially boost its reputation in the field of cancer research and clinical care.
The announcement of Veracyte presenting new data from its Afirma GSC at a prestigious event like the ATA Annual Meeting could potentially enhance its reputation in the field of cancer research and clinical care. This could lead to increased interest in the company's stock, potentially driving its price up in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100